Daniel E. Salazar, Ph.D.
Vice President of Clinical & Regulatory
Daniel E. Salazar Ph.D. is Brace Pharma Capital’s Vice President of Clinical & Regulatory and is also the Chief Scientific Officer and member of the Board of Directors at EMS S/A.
Dan has more than 25 years of experience in drug discovery, development, regulatory submissions and organizational leadership. He has made significant contributions to over 40 IND filings and 9 NDAs. He has co-authored over 80 publications and is an adjunct Associate Professor in the Department of Pharmaceutics at the University of Florida.
He was most recently Senior Vice President, Translational Medicine and Think Team at Otsuka Pharmaceutical Development. Dr. Salazar completed his undergraduate education at Princeton University where he majored in Biology and his Doctor of Pharmaceutical Science from the State University of New York at Buffalo.
Todd Brady
Director of Finance & Investments
Todd Brady is the Director of Finance and Investments at Brace Pharma Capital. He also serves as a director for Brace portfolio companies GeNO LLC, Avidity Biosciences and Tyrogenex, and formerly served as a board observer for Miragen Therapeutics.
Todd has an extensive and diverse background in Capital Markets, working in equity research, asset management, private equity and corporate banking over the duration of his career. Todd has a Masters of Business Administration from the Schulich School of Business (York University) and is a Chartered Financial Analyst (CFA).